293 related articles for article (PubMed ID: 28607581)
1. Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
Borcoman E; Le Tourneau C
Ther Adv Med Oncol; 2017 Jun; 9(6):431-439. PubMed ID: 28607581
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
Liu Y; Dong C; He X; Wu P; Shu Y; Chen L
BMC Nephrol; 2023 Mar; 24(1):51. PubMed ID: 36899322
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
7. Review Article: Immune Landscape and Immunotherapy Options in Cervical Carcinoma.
Kousar K; Ahmad T; Naseer F; Kakar S; Anjum S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139618
[TBL] [Abstract][Full Text] [Related]
8. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
9. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for the treatment of cervical cancer.
Marret G; Borcoman E; Le Tourneau C
Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
[No Abstract] [Full Text] [Related]
11. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
15. Top advances of the year: Cervical cancer.
Podwika SE; Duska LR
Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.
Youn JW; Hur SY; Woo JW; Kim YM; Lim MC; Park SY; Seo SS; No JH; Kim BG; Lee JK; Shin SJ; Kim K; Chaney MF; Choi YJ; Suh YS; Park JS; Sung YC
Lancet Oncol; 2020 Dec; 21(12):1653-1660. PubMed ID: 33271094
[TBL] [Abstract][Full Text] [Related]
18. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
19. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G; Manzano A; Casado A
Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies landscape and associated inhibitors for the treatment of cervical cancer.
Yadav A; Yadav S; Alam MA
Med Oncol; 2023 Oct; 40(11):328. PubMed ID: 37815596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]